{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.4","upperLimit":"52.3","value":"47.4"},{"groupId":"OG001","lowerLimit":"43.6","upperLimit":"53.5","value":"48.7"},{"groupId":"OG002","lowerLimit":"38.4","upperLimit":"54.1","value":"46.4"},{"groupId":"OG003","lowerLimit":"36.5","upperLimit":"46.4","value":"41.5"}]}],"title":"Survival rate at 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.8","upperLimit":"44.5","value":"39.6"},{"groupId":"OG001","lowerLimit":"35.6","upperLimit":"45.3","value":"40.5"},{"groupId":"OG002","lowerLimit":"29.6","upperLimit":"44.9","value":"37.3"},{"groupId":"OG003","lowerLimit":"27.9","upperLimit":"37.4","value":"32.6"}]}],"title":"Survival rate at 24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.0","upperLimit":"29.8","value":"24.7"},{"groupId":"OG001","lowerLimit":"25.8","upperLimit":"35.7","value":"30.7"},{"groupId":"OG002","lowerLimit":"16.6","upperLimit":"29.8","value":"22.9"},{"groupId":"OG003","lowerLimit":"15.8","upperLimit":"25.1","value":"20.2"}]}],"title":"Survival rate at 36 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"393"},{"groupId":"OG002","value":"153"},{"groupId":"OG003","value":"389"}],"units":"Participants"}],"description":"Percentage of participants who were alive at fixed time points (18, 24, and 36 months) after randomization. The estimated percentage of survival along with the 95% confidence interval were calculated using Kaplan-Meier technique on the full analysis set.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"NUMBER","populationDescription":"The FAS included all participants who were randomized. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"At 18, 24, and 36 months post-randomization. Assessed at the final analysis DCO (27Aug2021).","title":"Overall Survival (OS) at 18, 24, and 36 Months After Randomization","type":"SECONDARY","unitOfMeasure":"percentage of survival"}